GlassScriptPhysician profile
Louis C Thibodeaux
NPI 1922080308
$15,191.29
in general payments reported to CMS, 2019-2025
25 companies · $1,974 in 2025
The $1,974 reported for 2025 was more than what 81% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $399 · 2020: $1,248 · 2021: $2,110 · 2022: $3,169 · 2023: $2,132 · 2024: $4,160 · 2025: $1,974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,299 · Travel and Lodging: $967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,298.90 |
| Travel and Lodging | $967.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $5,548.07 | 2020-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Smith+Nephew, INC. | $4,433.18 | 2019-2025 | Stravix, Grafix Pl, Oasis |
| Intuitive Surgical, INC. | $1,386.11 | 2022 | |
| Organogenesis INC. | $707.99 | 2021-2025 | Puraply, Apligraf |
| Convatec INC. | $385.37 | 2024 | |
| Misonix INC | $284.60 | 2020-2021 | |
| Kci USA, INC. | $283.17 | 2021-2023 | Prevena, V.A.C.Ulta, V.A.C. Veraflo |
| Bioventus LLC | $280.56 | 2022-2025 | Xcell |
| Tela Bio, INC. | $269.74 | 2023-2024 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Paratek Pharmaceuticals, INC. | $249.51 | 2024-2025 | Nuzyra |
| Polarityte, INC. | $189.72 | 2019 | |
| Acera Surgical, INC. | $162.52 | 2024 | Restrata Wound Matrix |
| Reapplix INC. | $140.85 | 2024 | 3c Patch Kit - Box |
| Integra Lifesciences Corporation | $138.38 | 2020 | |
| Bard Peripheral Vascular, INC. | $131.27 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $113.24 | 2022-2023 | Dalvance |
| Solventum Corporation | $97.29 | 2024-2025 | Activ.A.C., V.A.C.Ulta |
| Davol INC. | $96.92 | 2021 | |
| Tosoh Bioscience, INC. | $95.00 | 2019 | |
| Polymedics Innovations INC. | $58.04 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.07 | 2023 | Gattex |
| Janssen Pharmaceuticals, INC | $27.68 | 2021-2022 | |
| Royal Biologics, INC. | $27.20 | 2025 | |
| Nuo Therapeutics | $18.29 | 2022 | |
| Baxter Healthcare | $16.52 | 2025 | Perclot |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Louis Thibodeaux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.